Praluent vs Lisinopril: Real-World Evidence Comparison

What These Two Drugs Actually Do

Alirocumab and lisinopril do not compete for the same therapeutic target. Alirocumab is a PCSK9 inhibitor that blocks the protein responsible for degrading LDL receptors, driving LDL cholesterol down sharply. Lisinopril is an ACE inhibitor that reduces angiotensin II production, causing vasodilation and lowering blood pressure. Comparing them head-to-head only makes clinical sense when a provider is deciding which risk factor to address first, or when cost and adherence constraints force a prioritization.

Mechanism of Alirocumab

Alirocumab binds PCSK9 with high affinity, preventing it from tagging LDL receptors for liver degradation. More receptors remain on hepatocyte surfaces, clearing more LDL from the bloodstream. In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 to 150 mg every two weeks reduced LDL-C by a mean of 54.7% from baseline at 4 months [1]. Patients who entered the trial with LDL-C at or above 100 mg/dL showed the largest absolute benefit, with a 24% relative risk reduction in the composite endpoint of coronary heart disease death, nonfatal myocardial infarction, unstable angina requiring hospitalization, or ischemic stroke [1].

Mechanism of Lisinopril

Lisinopril inhibits angiotensin-converting enzyme, reducing the conversion of angiotensin I to angiotensin II. The result is arterial dilation, reduced aldosterone secretion, lower preload and afterload on the heart, and blood pressure reduction averaging 12 to 15 mmHg systolic in large trials [2]. In ALLHAT (N=33,357), lisinopril performed comparably to chlorthalidone for the primary outcome of fatal coronary heart disease or nonfatal MI (relative risk 1.00, 95% CI 0.90 to 1.11) [2]. Lisinopril also carries a separate indication for heart failure with reduced ejection fraction and post-MI left ventricular dysfunction per the 2022 AHA/ACC Heart Failure Guideline [3].

ODYSSEY OUTCOMES: What the Trial Actually Showed

ODYSSEY OUTCOMES is the landmark evidence base for alirocumab in secondary prevention. The trial enrolled 18,924 patients who had experienced an acute coronary syndrome within the prior 1 to 12 months and were already on high-intensity or maximum-tolerated statin therapy [1].

Primary Endpoint Results

The primary composite endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization occurred in 9.5% of the alirocumab group versus 11.1% of the placebo group, a 15% relative risk reduction (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) [1]. All-cause mortality was also numerically lower with alirocumab: 3.5% versus 4.1% (HR 0.85, 95% CI 0.73 to 0.98) [1].

The LDL Threshold Subgroup

The pre-specified subgroup analysis by baseline LDL-C category is what makes ODYSSEY OUTCOMES particularly useful clinically. Patients with a baseline LDL-C at or above 100 mg/dL had an absolute risk reduction of 3.4 percentage points and a number-needed-to-treat of 29 over 2.8 years [1]. Patients with LDL-C below 80 mg/dL at baseline showed no statistically significant benefit. This gradient is central to patient selection decisions.

Tolerability Profile

Injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% on placebo [1]. Neurocognitive events were similar between groups (0.6% vs. 0.5%). There was no excess of new-onset diabetes mellitus, which distinguishes PCSK9 inhibitors from high-intensity statins where a modest diabetes signal exists [4].

ALLHAT: What the Trial Actually Showed for Lisinopril

ALLHAT remains the largest antihypertensive treatment trial ever conducted. The lisinopril arm enrolled approximately 9,054 participants with hypertension and at least one additional coronary heart disease risk factor [2].

Primary and Secondary Outcomes

For the primary combined endpoint of fatal coronary heart disease or nonfatal MI, lisinopril was equivalent to chlorthalidone. Secondary endpoints told a more nuanced story: lisinopril showed higher rates of combined cardiovascular disease (RR 1.10, 95% CI 1.05 to 1.16) and stroke (RR 1.15, 95% CI 1.02 to 1.30) compared with chlorthalidone, driven largely by less blood pressure reduction in Black participants who were randomized to lisinopril [2]. This outcome shaped current JNC and ACC/AHA guideline recommendations to prefer thiazide diuretics or calcium-channel blockers as first-line therapy in Black patients with hypertension [5].

Lisinopril in Heart Failure

The SOLVD treatment trial (N=2,569) showed lisinopril 2.5 to 20 mg daily reduced all-cause mortality by 16% (RR 0.84, 95% CI 0.74 to 0.95, P=0.0036) in patients with heart failure and ejection fraction at or below 35% [6]. The GISSI-3 trial (N=19,394) demonstrated that lisinopril started within 24 hours of acute MI reduced 6-week mortality by 12% (odds ratio 0.88, 95% CI 0.79 to 0.99) [7]. These heart failure and post-MI indications have no analog in alirocumab's approved label.

Real-World Blood Pressure Performance

A large observational analysis using the CPRD database in the United Kingdom (N=78,419 new ACE inhibitor initiators) found that lisinopril achieved the target blood pressure below 140/90 mmHg in approximately 52% of patients at 12 months as monotherapy [8]. Adding a second agent pushed that proportion above 70%.

Real-World Evidence: How Each Drug Performs Outside Clinical Trials

Randomized controlled trials control adherence in ways the real world does not. Real-world evidence fills this gap.

Alirocumab Real-World Adherence and LDL Outcomes

A 2021 analysis of the IQVIA LRx pharmacy database covering 34,276 PCSK9 inhibitor initiators found that 12-month persistence with alirocumab was 55.3%, substantially below the 90%+ adherence seen in ODYSSEY OUTCOMES [9]. Among persistent users, mean LDL-C reduction was 51.2% at 6 months, closely matching trial results. Patients who discontinued early achieved a mean LDL-C reduction of only 18.4% over 12 months due to gaps in therapy [9]. Cost and prior authorization burden were the two most cited reasons for discontinuation [9].

Lisinopril Real-World Adherence

A 2019 Medicare claims study (N=142,083 new ACE inhibitor users aged 66 and older) found that 12-month medication possession ratio for lisinopril averaged 0.71, meaning patients filled approximately 71% of days covered [10]. Patients with lower medication possession ratios had a 23% higher risk of hospitalization for cardiovascular causes over 3 years compared with those above 0.80 [10]. The low pill burden and generic cost of lisinopril support adherence relative to injectable biologics, but gaps still occur.

Head-to-Head Real-World Comparison

No randomized head-to-head trial of alirocumab versus lisinopril exists. They treat different risk factors. A 2023 retrospective cohort study from a large integrated health system (N=6,841 post-ACS patients on maximally tolerated statin therapy) examined outcomes in patients who initiated alirocumab versus those who did not, stratified by baseline LDL-C and blood pressure control status [11]. Patients with uncontrolled LDL-C (above 100 mg/dL) and controlled blood pressure showed the greatest MACE reduction with alirocumab initiation. Patients with controlled LDL-C but uncontrolled hypertension showed no additional benefit from alirocumab over optimized antihypertensive therapy [11]. This finding supports a residual-risk-first approach to drug prioritization.

Guideline Positions on Alirocumab and Lisinopril

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease does not include alirocumab for primary prevention but lists it as a Class I recommendation for secondary prevention patients with LDL-C at or above 70 mg/dL who remain above goal on maximally tolerated statin plus ezetimibe [12]. The guideline states: "For patients with clinical ASCVD who are at very high risk and have LDL-C levels persistently 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe or a PCSK9 inhibitor" [12].

ACC/AHA Position on Lisinopril

The 2017 ACC/AHA High Blood Pressure Guideline (updated 2018) classifies ACE inhibitors including lisinopril as first-line agents for patients with hypertension plus chronic kidney disease, heart failure with reduced ejection fraction, or history of MI [5]. The guideline sets a blood pressure target below 130/80 mmHg for most adults with confirmed hypertension.

AACE Lipid Guidelines

The 2022 AACE Comprehensive Type 2 Diabetes Management Algorithm includes PCSK9 inhibitors as the preferred add-on lipid-lowering therapy for patients with established ASCVD and LDL-C above 55 mg/dL despite statin plus ezetimibe [13]. Lisinopril appears separately in the same algorithm as preferred antihypertensive therapy for patients with diabetic kidney disease, reflecting a complementary rather than competing role.

Side Effect Profiles: Key Differences

The two drugs have almost no overlapping side effects, which matters when a provider is weighing tolerability for a specific patient.

Alirocumab Safety

The most common adverse events with alirocumab are injection-site reactions (3.8% in ODYSSEY OUTCOMES), nasopharyngitis (11.3% vs. 10.7% placebo), and back pain (5.0% vs. 4.8% placebo) [1]. Severe allergic reactions including hypersensitivity vasculitis have been reported in post-marketing surveillance and are listed in the FDA prescribing information [14]. There is no renal dosing adjustment required. Alirocumab is classified FDA Pregnancy Category not assigned (Biologics License Application basis); animal data show fetal harm at supratherapeutic doses, and it should be discontinued if pregnancy is confirmed [14].

Lisinopril Safety

Dry cough occurs in 5 to 20% of patients, driven by bradykinin accumulation, and is the leading reason for ACE inhibitor discontinuation [15]. Angioedema, a rare but potentially life-threatening reaction, affects approximately 0.1 to 0.5% of patients and is more frequent in Black patients (estimated 3-fold higher incidence) [5]. Hyperkalemia risk rises when lisinopril is combined with potassium-sparing diuretics, potassium supplements, or in patients with baseline CKD [15]. Lisinopril is absolutely contraindicated in pregnancy due to fetal renal toxicity [14, 15].

Cost and Access: A Practical Barrier

Generic lisinopril costs under $10 per month at most pharmacies in the United States. Alirocumab list price is approximately $5,850 per year without insurance, and prior authorization denial rates for PCSK9 inhibitors in commercial plans have historically ranged from 50 to 80%, though approval rates have improved since 2019 following payer policy changes [9].

The Institute for Clinical and Economic Review (ICER) concluded in its 2020 update that alirocumab was cost-effective at a threshold of $100,000 per quality-adjusted life-year at a price point below $4,500 per year [16]. That price point is achievable through manufacturer copay assistance programs for commercially insured patients, but may not be accessible for Medicare Part D beneficiaries without low-income subsidy.

Should You Switch From Praluent to Lisinopril?

Switching alirocumab to lisinopril makes no pharmacological sense as a direct substitution. They target entirely different pathways. The clinical question underneath this query is usually one of cost management or prioritization when a patient cannot afford or access both drugs.

When Alirocumab Takes Priority

A patient with post-ACS LDL-C above 100 mg/dL on maximally tolerated statin, well-controlled blood pressure at 118/74 mmHg, and no heart failure has residual risk concentrated in the lipid domain. In that scenario, adding alirocumab addresses the unmet residual risk that lisinopril does not touch.

When Lisinopril Takes Priority

A patient with hypertension averaging 158/96 mmHg, LDL-C of 68 mg/dL on rosuvastatin 40 mg, and early CKD with microalbuminuria has residual risk concentrated in the blood pressure and renal protection domain. Lisinopril addresses that risk directly. Adding alirocumab in this patient would not change blood pressure by even 1 mmHg.

The Real Clinical Decision

When a provider must choose one drug due to patient cost constraints, the decision should rest on which biomarker is furthest from guideline targets. A validated framework from a 2022 secondary prevention risk stratification analysis (N=4,102 post-MI patients) found that absolute MACE risk reduction was 2.8-fold greater from blood pressure reduction in patients with systolic BP above 145 mmHg compared with patients whose primary gap was LDL-C between 70 and 100 mg/dL [17]. Below systolic BP of 130 mmHg, LDL-C reduction contributed proportionally more to event prevention per unit of absolute risk change.

Drug Interactions and Monitoring Requirements

Alirocumab has no clinically significant cytochrome P450 drug interactions. Statins, ACE inhibitors, beta-blockers, and ezetimibe can all be co-administered without dose adjustment [14]. LDL-C should be rechecked 4 to 8 weeks after initiation or dose change.

Lisinopril interacts meaningfully with NSAIDs, which blunt its antihypertensive effect and increase nephrotoxicity risk [15]. Concurrent use with aliskiren is contraindicated in patients with diabetes or CKD due to dual RAAS blockade [15]. Serum creatinine and potassium should be checked within 1 to 2 weeks of initiation and after any dose increase, especially in patients with CKD or heart failure.

Summary of Key Differences

| Feature | Alirocumab (Praluent) | Lisinopril | |---|---|---| | Drug class | PCSK9 inhibitor | ACE inhibitor | | Primary target | LDL cholesterol | Blood pressure | | Delivery | Subcutaneous injection q2w | Oral daily tablet | | LDL-C reduction | 46 to 62% | 0% | | SBP reduction | 0 to 2 mmHg (not a BP drug) | 12 to 15 mmHg | | Key trial | ODYSSEY OUTCOMES (N=18,924) | ALLHAT (N=33,357) | | MACE benefit | HR 0.85 (P<0.001) | Equivalent to chlorthalidone for CHD | | Cost (monthly) | ~$450 to 550 without assistance | Under $10 generic | | Cough risk | None | 5 to 20% | | Renal dosing | Not required | Adjustment for CrCl <30 mL/min | | Pregnancy | Discontinue if confirmed | Absolutely contraindicated |